Articles tagged with Drug Interactions
Researchers at CeMM and Pfizer have developed a novel method to measure the binding activity of hundreds of small molecules against thousands of human proteins. The study revealed tens of thousands of ligand-protein interactions that can now be explored for drug development.
Researchers developed a prediction tool to classify proteins based on their potential to bind RNA G-quadruplexes, showing high protein disorder and hydrophilicity. This discovery provides insights into gene expression and phase-separation into membrane-less organelles.
Older people with HIV are more likely to have comorbidities and become frail compared to their age groups without HIV. By 65 years old, around 70% of those living with HIV for 20 years or more are living with multiple conditions.
A study of 104 patients found that 83.5% had divergent phenotypes, with a significant increase in CYP2D6 poor metabolizers due to phenoconversion. The results highlight the importance of pharmacogenetic testing and personalized treatment approaches in psychiatric care.
Researchers discovered GZ17-6.02's ability to interact with proteasome inhibitors in a greater than additive fashion to kill multiple myeloma cells and alone inhibit inhibitor-resistant cells. The compound combination also activated key pathways and increased autophagosome formation, leading to tumor cell killing.
A study published in the journal Med found that sensory nerves accelerate tumor growth by suppressing specific immune cells within the tumor microenvironment. Blocking nerve activity with FDA-approved drugs like botox or gabapentin can stop cancer progression for about six weeks, and may have synergistic effects with radiation treatment.
Researchers found GZ17-6.02 alone and in combination with standard-of-care agents was effective in killing MF cells, activating key pathways including ATM, AMPK, NFκB, and macroautophagy. The compound's unique multi-factorial mechanism suggests potential for treating mycosis fungoides.
Researchers developed a multipronged strategy to identify transporters used by different drugs, revealing potential interactions between commonly prescribed antibiotics and blood thinners. The approach has the potential to improve patient treatment and predict potential toxicities.
A new study lists 16 medications with high risks and recommends safer alternatives for older people. The Australian PIMs list provides a resource to help clinicians identify risky medications and improve medication management.
A new poll found that only 7.5% of people between 50-80 have used at least one direct-to-consumer health care service, with most receiving prescriptions for a one-time treatment. Many users didn't inform their regular providers about the prescriptions.
Clinicians use specific cues to detect and address drug-drug interactions, which can be addressed by investigating alternative treatments, altering dosage, or stopping a medication. The study provides recommendations for EHR system alert design to improve clinician decision-making and patient safety.
A study found that the common drug Entresto (sacubitril/valsartan) increases plasma Aβ42 and Aβ40 levels in patients with cardiac failure, making them falsely positive on a debated Alzheimer's blood test. This could lead to misclassification of patients as having Alzheimer's disease.
A new study published in Cannabis and Cannabinoids Research found that 12% of people aged 50-80 have consumed a THC-containing substance in the past year. Those who drink alcohol at risky levels have a higher rate of cannabis use, highlighting the need for education and screening for older adults.
Researchers investigate nanoparticles for cancer treatment, hoping to reduce side effects and improve efficacy. La-Beck's lab aims to understand the body's interaction with nanoparticles and their impact on tumor growth and immune responses.
Experts call for urgent measures to address discrimination against patients fleeing war or conflict zones, those with serious mental illnesses, and frail elderly patients. Guidelines for treating advanced breast cancer should prioritize patient preferences and involve multidisciplinary care teams.
The Cusack group at EMBL Grenoble has provided insights into the interactions of XIAP and RIPK2 molecules involved in gut signalling pathways. This research sheds light on how these molecules interact, revealing a promising drug target for treating inflammatory bowel diseases.
Analysis of over 1 million Danish inpatients reveals nearly 4,000 drug pairs linked to increased dosage adjustments and potential harmful interactions. The study suggests previously undiscovered interactions among these pairs, highlighting the importance of considering dosage when evaluating polypharmacy.
A team of Chinese and UK researchers has identified superoxide dismutase 1 (SOD1) as a potential target for reversing drug resistance in ovarian cancer. By using nanoparticles to deliver siRNA that reduces SOD1 levels, the study showed reduced growth and decreased resistance to cisplatin in female mice.
A new study published in eLife reveals the folding speed limit of helical membrane proteins using a robust single-molecule tweezer method. The findings provide unprecedented insights into structural states, kinetics, and energy barrier properties, offering valuable guidance for advancing pharmaceutical research and design.
A new study uses machine learning to analyze data from DrugAge, a database of chemical compounds modulating lifespan in model organisms. The researchers create four types of datasets to predict whether or not a compound extends the lifespan of C. elegans, using features such as compound-protein interactions and Gene Ontology terms.
Researchers have found that PD-L1 triggers signaling that intrinsically alters cancer cell phenotype, impacting immune milieu. The study's findings suggest a new approach to treating patients with limited response to immunotherapy.
The American College of Chest Physicians (CHEST) has released a new clinical guideline for managing antithrombotic therapy in patients with COVID-19-related arterial thrombosis and thromboembolism. The guideline provides evidence-based recommendations to improve risk-evaluation and treatment course.
A new NIH study suggests xylazine, a veterinary tranquilizer, can damage brain oxygen levels when combined with opioid drugs like fentanyl and heroin. This combination may lead to prolonged brain oxygen decreases, increasing overdose risk. Researchers hope to develop interventions to reverse overdoses and save lives.
A new study published in JNCCN found that taking alectinib, a medication for advanced lung cancer, with a full breakfast or lunch resulted in higher drug concentrations than with a low-fat breakfast. This could impact treatment efficacy and survival rates for patients.
Researchers developed a mass spectrometry method to analyze molecular glues and assess their relative strengths. The technique enables the elucidation of mechanisms through which these molecules stabilize protein interactions.
Interactions between gut bacteria may limit antibiotics' effectiveness in treating C. difficile infections, a study suggests. Researchers found that certain bacterial species make the bacterium tolerant to metronidazole and increase its abundance.
A study published in Microorganisms shows that melatonin can aggravate Crohn's disease and ulcerative colitis by disrupting the balance of gut microbiota. The hormone, commonly used to improve sleep, had negative effects on bowel inflammation in laboratory mice, depending on their microbiota profile.
Researchers found a partial response in a patient with pancreatic acinar cell carcinoma, as well as stable disease in 11 patients, when combining riluzole with sorafenib in a phase I trial. The combination was safe and tolerable, and further exploration of its potential is warranted.
Researchers at Argonne National Laboratory and University of Chicago developed a hybrid simulation process using IBM quantum computers to solve electronic structure problems. The new method uses classical processing to mitigate noise generated by the quantum computer, paving the way for future improvements.
Human macrophages use Siglec-14 receptors to recognize and engulf carbon nanotubes, leading to inflammation. The discovery could pave the way for developing safer carbon nanotubes and therapies to prevent inflammatory diseases.
A novel database, CycPeptMPDB, has been created to facilitate the development of drugs based on cyclic peptides. The database contains information on thousands of cyclic peptides and their membrane permeability values, enabling researchers to select candidate peptides that can penetrate human cell membranes.
A KAIST research team has developed an advanced AI-based drug interaction prediction technology that analyzed the interaction between Paxlovid ingredients and other prescription drugs. The study identified potential drug-drug interactions and alternative drugs with low adverse effects, which can aid in developing new treatments.
A new study published in The Lancet found that an existing drug, sulfadoxine-pyrimethamine, protects pregnant women from sexually transmitted and reproductive tract infections. Researchers tested this drug alongside a promising new treatment, dihydroartemisinin-piperaquine, which showed unique ability to prevent malaria.
Researchers have developed a new ultrafast infrared spectroscopy method that can detect molecular vibration information at high speeds. This method, called upconversion time-stretch infrared spectroscopy (UC-TSIR), provides over 30-fold more spectral elements and 400 times better spectral resolution than conventional methods.
Researchers at Karolinska Institutet have developed a new approach to treating inflammatory diseases by analyzing the activity of genes in individual cells. This digital twin technology could lead to personalized drug therapies for patients with conditions like rheumatoid arthritis, Crohn's disease, and ulcerative colitis.
Researchers created a network of interacting proteins to understand the function of genes and link specific biological processes to diseases. They identified groups of proteins interacting with genes linked to over 1,000 human traits, providing insights into new targets for drug discovery and potential repurposing opportunities.
Researchers investigated psychostimulants' effects on dopamine transporter, discovering persistent binding determines sustained effects. The study found that varying binding times between substances result in different durations and intensities of effects.
The study found that implementing the Shed-MEDS protocol before discharge to a post-acute care facility reduced patients' medication burden. The intervention also decreased exposure to potentially inappropriate medications, with effects persisting for at least 90 days.
Preterm birth increases the risk of cardiovascular problems; combining steroids with statins could eliminate negative effects while retaining respiratory benefits. Researchers found that combined therapy improved lung function and reduced cardiovascular issues in rat pups.
A potent plant toxin called albicidin has emerged as a strong new antibiotic candidate, effective in small concentrations and highly potent against pathogenic bacteria. Its unique mechanism targets the bacterial enzyme DNA gyrase, which is essential for cell function.
Laboratory experiments show rapid antibiotic switches can prevent resistance, with collateral-sensitive drug pairs suitable for therapy. However, environmental conditions in patients differ from labs, and natural degradation affects treatment.
Researchers from KAIST and Chungnam National University have developed a new equation to predict drug interactions, improving accuracy by 80% compared to the existing FDA formula. The new equation takes into account factors such as gut bioavailability and enzyme concentration.
Researchers have improved the FDA's equation for predicting drug interactions by addressing fundamental limitations and incorporating new models. The modified equation has shown a significantly increased accuracy of about 80%, which is expected to contribute to increasing the success rate of new drug development.
Researchers discovered that enterococci, a type of antibiotic-resistant bacteria, can make C. difficile more potent and dangerous by producing amino acids. This understanding could help doctors identify patients at risk and develop new treatments for the deadly infection.
Research from University of Virginia Health System suggests antidepressants can heighten lifelong brain changes in babies, such as autism, when combined with infection or inflammation during pregnancy. SSRIs interact powerfully with the mother's body, causing harmful changes in the placenta and developing brain.
As people age, their health care needs become more complex, making it essential to consider anatomical and functional changes when diagnosing and treating ACS. An individualized and patient-centered approach is best for older adults, considering coexisting conditions and input from multiple specialists.
Scientists create an artificial brain in a petri dish to study the effects of the Zika virus. The study reveals that viral noncoding RNA helps the virus evade antiviral responses and cause cell death in developing brains.
A new American Heart Association scientific statement highlights the potential benefits and risks of complementary and alternative therapies for heart failure. The statement advises healthcare professionals to discuss CAM use with patients, monitor medication interactions, and consider pharmacists' consultations.
A retrospective cohort study of 1,404 subjects with type 2 diabetes found that metformin use reduced the risk of delirium by 50% and decreased 3-year mortality rates. The study suggests that metformin may be a potential benefit for patients with diabetes, particularly in reducing age-related disorders such as dementia.
Researchers at IRB Barcelona have developed a new tool to block protein-protein interactions, a potential therapeutic approach for diseases such as prostate cancer. The synthetic molecules mimic the binding surface of proteins, offering high versatility and stability.
Researchers identified USP7 as a novel cyclin F-interacting protein that stabilizes cyclin F protein. The study also found that USP7 regulates cyclin F mRNA, with pharmacological inhibition resulting in downregulation of cyclin F mRNA.
Researchers at Weill Cornell Medicine have discovered a mechanism by which lipids regulate pacemaker ion channel proteins in the heart. By disrupting a specific molecular connection, certain lipids can enhance pacemaker channel activity, leading to potential treatments for cardiac arrhythmias and other conditions.
Researchers at the University of Cincinnati are awarded a $3.5 million NIH grant to examine how alcohol use alone or in combination with fentanyl affects HIV medications, including PrEP medication. The study aims to determine metabolite signatures and pharmacological biomarkers of PrEP in HIV-negative populations.
A comprehensive study reveals SARS-CoV-2 viral-to-human protein interaction network, showing how the virus hijacks human proteins. Researchers identified 23 candidate drugs, including an FDA-approved beta-blocker that shows promise in inhibiting viral infection.
The Rutgers team developed an analytical toolkit to measure protein-carbohydrate interactions with single-molecule precision. By adjusting the 'stickiness' of enzymes, they aim to enhance cellulose decomposition for biofuels production and improve healthcare targeting protein-based drugs.
A review paper calls for health system drug interaction alerts for heart disease patients being treated for COVID-19. Experts highlight the importance of awareness and availability of alternative treatment options to mitigate severe adverse effects.
A recent study analyzed the records of over 33,000 dementia patients in Wales and found that those closest to their diagnosis were taking an average of three or more medications. This suggests a possible link between polypharmacy and the development of dementia.
A Cleveland Clinic-led research team created a discovery tool outlining interactions between COVID-19 and host proteins, identifying potential host-targeting therapies. The study confirmed over 200 interactions and discovered new ones, highlighting promising approaches for treating COVID-19.
The study reveals how the activating partner PI5P interacts with two different regions of regulatory protein UHRF1, showing its role in modulating complex proteins. This finding could breathe new life into the search for UHRF1-directed medicines.
Researchers developed an AI-based screening method that models drug and target protein interactions using natural language processing techniques. The technique achieved high accuracy in identifying promising drug candidates, which can accelerate the exploration of new medicines and repurpose existing ones.